Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Authors
Keywords
-
Journal
Nature Communications
Volume 7, Issue -, Pages 13354
Publisher
Springer Nature
Online
2016-10-31
DOI
10.1038/ncomms13354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Nivolumab for the treatment of cancer
- (2014) Anasuya Gunturi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Antitumour immunity gets a boost
- (2014) Jedd D. Wolchok et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View
- (2013) Shi Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering
- (2010) Chao Yu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epitope Landscape in Breast and Colorectal Cancer
- (2008) N. H. Segal et al. CANCER RESEARCH
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation